Evidence map›Paper›PMID 38742621›Full record

ArticleThe Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry2025

Gustav Oppenheim (1882-1937) and the Discovery of Cerebral Amyloid Angiopathy.

Anthony Maurice Ness, Judd Aiken

Abstract readHistorical Article
In one paragraph

Article in The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anthony Maurice NessDepartment of Biological Sciences, Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Canada.ORCID 0000-0003-1329-8435
Judd AikenDepartment of Agricultural, Food & Nutritional Science, Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of cerebral amyloid angiopathy (CAA) is frequently attributed to Dr. Gustav Oppenheim-a man who has been largely passed over in history. Oppenheim's clinical and neuropathologic research covered a variety of disorders, but his name is best known for his work on senile dementia and CAA. Although Oppenheim was in fact not the first to discover CAA, his neuropathologic observations and inferences on neurodegenerative disease proved to be remarkably faithful to our modern understanding of neurodegenerative diseases. As a neurologist, he served in the First World War and was later subjected to religious persecutions in the leadup to the Holocaust but was not fortunate enough to emigrate before his death. The life, social impact, and previously overlooked contributions to science and medicine by Oppenheim are detailed.

Indexed as

Cerebral Amyloid AngiopathyNeurologyHistory, 19th CenturyHistory, 20th CenturyHumansAlzheimer diseaseamyloid βcerebral amyloid angiopathyhistory of medicineneurologyneuroscience

Identifiers

PMID38742621
PMCPMC12103639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.